top of page

Research & Commentary

The Hidden Burden of MCS/IEI — Psychosocial and Occupational Consequences in Qualitative Research

Chemical Intolerance

Gene Expression Dynamics in MCS — Insights from Controlled n‑Butanol Exposure

Chemical Intolerance

Neuroimaging Evidence of Olfactory-Limbic Alterations in MCS — Bridging Sensory Processing and Environmental Intolerance

Chemical Intolerance

Genetic Polymorphisms in Detoxification and Oxidative Stress Pathways—Modest but Meaningful Clues in MCS Susceptibility

Chemical Intolerance

The Italian Expert Consensus on MCS/TILT/IEI — Toward a Structured Clinical and Therapeutic Framework

Chemical Intolerance

Epidemiologic Evidence Supporting the TILT–Mast Cell Activation Connection

Chemical Intolerance

The QEESI Questionnaire — A Validated Tool for Assessing Chemical Intolerance and TILT

Chemical Intolerance

Toxicant-Induced Loss of Tolerance (TILT) as a Unifying Model for Environmental Illness

Chemical Intolerance

Linking Mast Cell Activation to Chemical Intolerance — A Mechanistic Shift in Environmental Sensitivity Paradigms

Chemical Intolerance

Integrative Perspectives on the Pathophysiology of Multiple Chemical Sensitivity

Chemical Intolerance

Examining the Position Multiple Chemical Sensitivities

Intranasal Antihistamines Versus Corticosteroids in Allergic Rhinitis

Exacerbations in pediatric patients on mepolizumab are linked to activated sputum eosinophils.

This raises the possibility that subpopulations of airway eosinophils exist that contribute to breakthrough exacerbations.

Are sputum eosinophil levels predictive of a poor response to mepolizumab?

Eosinophils have multiple functions; they play an important role in host defense against parasitic, viral, fungal, and bacterial infections, and they also maintain homeostasis in the stable conditions.

Immune‑Metabolic Crosstalk in Atopic Dermatitis—TSLP, Sebaceous Glands, and Barrier Integrity

Atopic dermatitis (AD) is a chronic inflammatory disorder causing substantial physical, psychological, and socioeconomic burdens, with a notable prevalence in various regions. It manifests with symptoms such as pruritis, erythematous patches, crusting, scaling, fissuring, and lichenification, with lesion distribution varying between pediatric and adult populations.

Asthma-COPD existence

The balance of evidence now favors the view that asthma and COPD are distinct diseases that have differing genetic predispositions but may coexist in an indi- vidual, as both diseases commonly occur in the population and asthma may predispose to development of COPD.

Childhood asthma rates in Australian cities are more strongly associated with socioeconomic status than with air pollution or environmental conditions.

There is overwhelming evidence that the gaps in asthma prevalence and severity between economically advantaged and disadvantaged children can be linked to socioeconomic status (SES) and disparities in their living conditions or exposures

An LNP-CRISPR gene-editing therapy shows safety and efficacy in hereditary angioedema patients after in vivo delivery.

An LNP-CRISPR gene editing drug demonstrates efficacy and safety in patients with hereditary angioedema following in vivo administration

PEGylated Liposomes as a Diagnostic Tool for Polyethylene Glycol Allergy

Presentation of polyethylene glycol (PEG) on the surface of a lipid nanoparticle increases its in vivo and ex vivo allergenicity, and improves diagnosis of PEG allergy.

Role of ITIH4 as a Compensatory Protease Inhibitor in Hereditary Angioedema

$Covered topics include contextualization of MCAS and MCAS-like endotypes and related diagnostic evaluations; mechanistic research; management of typical and refractory symptoms; and MCAS-specific education for patients and health care providers.$

Mast Cell Activation Syndrome Update—A Dermatology

In recent years, the term MC activation syndrome (MCAS) was proposed to account for symptoms caused by MC activation, and clear diagnostic criteria have been defined. However, not all authors agree with these criteria, as some find them too restrictive, potentially leaving much of the MC-related pathology unaccounted for. Here, we review the current knowledge on the physiological and pathological roles of MCs, with a dermatological emphasis, and discuss the MCAS classification.

Mast Cell Activation Syndromes

It emphasizes the necessity of standardized diagnostic criteria for MCAS, as most patients fulfilling MCAS criteria also meet the clinical definition of anaphylaxis.

Current Perspectives on Mast Cell Activation Syndromes: Collegium Internationale Allergologicum 2022 Update

Mast cell activation syndromes (MCASs) are defined by systemic severe and recurrent mast cell activation, usually in form of anaphylaxis, a substantial, event-related increase of the serum tryptase level beyond the individual's baseline and a response of the symptomatology to drugs directed against mast cells, mast cell-derived mediators, or mediator effects.

AAAAI Work Group Report on Diagnosis and Management of Mast Cell Activation Syndrome (MCAS)

Mast cell activation syndrome; anaphylaxis; c-kit; hereditary α-tryptasemia; histamine; leukotriene C(4); mastocytosis; prostaglandin D(2); tryptase.

Mast Cell Activation Syndrome: Diagnostic

Towards a global classification for mast cell disorders

bottom of page